Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFUL.L Regulatory News (FUL)

  • There is currently no data for FUL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Hardman & Co Research: The Fulham Shore (FUL) - Investor Forum company research (Nov 2021)

6 Dec 2021 12:05

Hardman & Co Research Hardman & Co Research: The Fulham Shore (FUL) - Investor Forum company research (Nov 2021) 06-Dec-2021 / 12:05 GMT/BST


Hardman & Co November 2021 Investor Forum company presentation:

The Fulham Shore Plc (FUL)

On 18 November we were delighted to host our final Investor Forum of the year. At the live event, management of Fulham Shore rounded the company presentations off with an upbeat view of what the consumer/restaurant industry has to offer investors in a post COVID-19 world. After taking investors through its robust internal culture and policies, which have helped transition the company through the very difficult sector trading period, management outlined its significant UK expansion plans for Franco Manca and The Real Greek as well as its international franchising ambitions.

 We would like to share with you the research note and slide pack, along with the recording of the presentation.

Read FUL research note | Download FUL slide pack |

Watch FUL forum recording

If you are interested in meeting the company, you can register your interest by clicking here.

To contact us:

Hardman & Co1 Frederick's Place

London

EC2R 8AE

www.hardmanandco.com

Follow us on Twitter @HardmanandCo

Contact:

Jason Streets

Mike Foster+44 20 3693 7075

 

js@hardmanandco.com

mf@hardmanandco.com  

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

 


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1254468 06-Dec-2021 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
10th Jan 20087:01 amRNSProposed Board Changes
20th Dec 20075:35 pmRNSResult of AGM
26th Nov 20077:01 amRNSFinal Results
15th Nov 20077:01 amRNSNotice of Results/Trdg Update
6th Nov 20077:01 amRNSOpening of new US office
11th Oct 20077:01 amRNSContract Win
7th Sep 20077:01 amRNSRe Alliance
3rd Sep 20074:13 pmRNSDirector/PDMR Shareholding
20th Aug 20074:09 pmRNSDirector/PDMR Shareholding
17th Aug 20074:37 pmRNSAIM Rule 26
15th Aug 20077:01 amRNSTrading Update
17th May 20077:01 amRNSInterim Results
18th Apr 20074:46 pmRNSDirector/PDMR Shareholding
12th Apr 20071:40 pmRNSEGM Statement
19th Mar 200711:28 amRNSPlacing and Acquisition
21st Feb 20077:00 amRNSCompletion of Earn Out
21st Dec 20069:29 amRNSTotal Voting Rights
18th Dec 200612:52 pmRNSResult of AGM
15th Nov 20062:06 pmRNSDirector/PDMR Shareholding
9th Nov 20067:01 amRNSFinal Results
2nd Aug 20067:00 amRNSDirector/PDMR Shareholding
12th May 20067:01 amRNSEdinburgh Office Opens
9th May 20067:01 amRNSInterim Results
12th Apr 200610:30 amRNSContract with Celtic Pharma
5th Apr 20067:01 amRNSNanoCarrier Partnership
7th Mar 20067:01 amRNSBoard Appointment
9th Feb 20067:01 amRNSAcquisition of Quadramed Ltd
19th Dec 200512:09 pmRNSAGM Statement
14th Nov 200512:18 pmRNSDirector/PDMR Shareholding
9th Nov 20057:00 amRNSPreliminary Results
14th Sep 20057:02 amRNSTrading Update
18th May 20057:01 amRNSSyngenta Biopharma Agreement
18th May 20057:00 amRNSInterim Results
5th May 200512:20 pmRNSNotice of Interim Results
1st Mar 20057:03 amRNSPresent at Networking Evening
25th Jan 20057:00 amRNSPresentation with Addex
6th Jan 20057:00 amRNSBoard Appointment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.